These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 25662600)

  • 1. [Systemic treatment of brain metastases from breast cancer].
    Taillibert S; Conforti R; Bonneterre J; Bachelot T; Le Rhun E; Bernard-Marty C
    Cancer Radiother; 2015 Feb; 19(1):36-42. PubMed ID: 25662600
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A systematic review of trastuzumab and lapatinib in the treatment of women with brain metastases from HER2-positive breast cancer.
    Larsen PB; Kümler I; Nielsen DL
    Cancer Treat Rev; 2013 Nov; 39(7):720-7. PubMed ID: 23481218
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Her2 positive breast cancer: practices].
    Campone M; Berton-Rigaud D; Bourbouloux E; Sophie S; Zanetti A; Frenel JS
    Bull Cancer; 2011 Feb; 98(2):154-63. PubMed ID: 21591301
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined targeting of HER2 and VEGFR2 for effective treatment of HER2-amplified breast cancer brain metastases.
    Kodack DP; Chung E; Yamashita H; Incio J; Duyverman AM; Song Y; Farrar CT; Huang Y; Ager E; Kamoun W; Goel S; Snuderl M; Lussiez A; Hiddingh L; Mahmood S; Tannous BA; Eichler AF; Fukumura D; Engelman JA; Jain RK
    Proc Natl Acad Sci U S A; 2012 Nov; 109(45):E3119-27. PubMed ID: 23071298
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Systemic treatment of brain metastases from breast cancer: cytotoxic chemotherapy and targeted therapies].
    Bachelot T; Le Rhun E; Labidi-Gally I; Heudel P; Gilabert M; Bonneterre J; Pierga JY; Gonçalves A
    Bull Cancer; 2013 Jan; 100(1):7-14. PubMed ID: 23305997
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Radiotherapy plus concomitant systemic therapies for patients with brain metastases from breast cancer].
    Cao KI; Kirova YM
    Cancer Radiother; 2014 Jun; 18(3):235-42; quiz 246, 249. PubMed ID: 24731405
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Trastuzumab emtansine in the systemic treatment of HER-2-positive breast cancer brain metastases].
    Frenel JS; Bally O; Bourbouloux E; Berton-Rigaud D; Campone M; Bachelot T; Heudel PÉ
    Bull Cancer; 2016 May; 103(5):507-10. PubMed ID: 26992855
    [No Abstract]   [Full Text] [Related]  

  • 8. Overall survival and the response to radiotherapy among molecular subtypes of breast cancer brain metastases treated with targeted therapies.
    Miller JA; Kotecha R; Ahluwalia MS; Mohammadi AM; Chao ST; Barnett GH; Murphy ES; Vogelbaum MA; Angelov L; Peereboom DM; Suh JH
    Cancer; 2017 Jun; 123(12):2283-2293. PubMed ID: 28192598
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): a randomised, open-label, multicentre, phase 2 trial.
    Cortés J; Dieras V; Ro J; Barriere J; Bachelot T; Hurvitz S; Le Rhun E; Espié M; Kim SB; Schneeweiss A; Sohn JH; Nabholtz JM; Kellokumpu-Lehtinen PL; Taguchi J; Piacentini F; Ciruelos E; Bono P; Ould-Kaci M; Roux F; Joensuu H
    Lancet Oncol; 2015 Dec; 16(16):1700-10. PubMed ID: 26596672
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase II study of lapatinib for brain metastases in patients with HER2-overexpressing breast cancer following trastuzumab based systemic therapy and cranial radiotherapy: subset analysis of Japanese patients.
    Iwata H; Narabayashi M; Ito Y; Saji S; Fujiwara Y; Usami S; Katsura K; Sasaki Y
    Int J Clin Oncol; 2013 Aug; 18(4):621-8. PubMed ID: 23011099
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Survival benefit of anti-HER2 therapy after whole-brain radiotherapy in HER2-positive breast cancer patients with brain metastasis.
    Zhang Q; Chen J; Yu X; Cai G; Yang Z; Cao L; Hu C; Guo X; Sun J; Chen J
    Breast Cancer; 2016 Sep; 23(5):732-9. PubMed ID: 26267412
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase I study of lapatinib with whole brain radiotherapy in patients with Human Epidermal Growth Factor Receptor 2 (HER2)-positive breast cancer brain metastases.
    Lin NU; Freedman RA; Ramakrishna N; Younger J; Storniolo AM; Bellon JR; Come SE; Gelman RS; Harris GJ; Henderson MA; Macdonald SM; Mahadevan A; Eisenberg E; Ligibel JA; Mayer EL; Moy B; Eichler AF; Winer EP
    Breast Cancer Res Treat; 2013 Nov; 142(2):405-14. PubMed ID: 24197661
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical outcomes in patients who received lapatinib plus capecitabine combination therapy for HER2-positive breast cancer with brain metastasis and a comparison of survival with those who received trastuzumab-based therapy: a study by the Anatolian Society of Medical Oncology.
    Kaplan MA; Isikdogan A; Koca D; Kucukoner M; Gumusay O; Yildiz R; Dayan A; Demir L; Geredeli C; Kocer M; Arslan UY; Inal A; Akman T; Coskun U; Sener N; Inanc M; Elkiran ET; Ozdemir NY; Durnalı AG; Suner A; Alici S; Tarhan MO; Boruban C; Oksuzoglu B; Urakci Z
    Breast Cancer; 2014 Nov; 21(6):677-83. PubMed ID: 23335064
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic factors of brain metastases from breast cancer: impact of targeted therapies.
    Braccini AL; Azria D; Thezenas S; Romieu G; Ferrero JM; Jacot W
    Breast; 2013 Oct; 22(5):993-8. PubMed ID: 23831232
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A systematic review of dual targeting in HER2-positive breast cancer.
    Kümler I; Tuxen MK; Nielsen DL
    Cancer Treat Rev; 2014 Mar; 40(2):259-70. PubMed ID: 24080156
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic approach to the management of HER2-positive breast cancer metastatic to the brain.
    Patil A; Sherbet GV
    Cancer Lett; 2015 Mar; 358(2):93-99. PubMed ID: 25529010
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lapatinib plus capecitabine resolved human epidermal growth factor receptor 2-positive brain metastases.
    Glück S; Castrellon A
    Am J Ther; 2009; 16(6):585-90. PubMed ID: 19287304
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Brain metastases in Asian HER2-positive breast cancer patients: anti-HER2 treatments and their impact on survival.
    Yap YS; Cornelio GH; Devi BC; Khorprasert C; Kim SB; Kim TY; Lee SC; Park YH; Sohn JH; Sutandyo N; Wong DW; Kobayashi M; Landis SH; Yeoh EM; Moon H; Ro J
    Br J Cancer; 2012 Sep; 107(7):1075-82. PubMed ID: 22918394
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic breast cancer.
    Orlando L; Cardillo A; Ghisini R; Rocca A; Balduzzi A; Torrisi R; Peruzzotti G; Goldhirsch A; Pietri E; Colleoni M
    BMC Cancer; 2006 Sep; 6():225. PubMed ID: 16978400
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HER2-positive metastatic breast cancer: a changing scenario.
    Mustacchi G; Biganzoli L; Pronzato P; Montemurro F; Dambrosio M; Minelli M; Molteni L; Scaltriti L
    Crit Rev Oncol Hematol; 2015 Jul; 95(1):78-87. PubMed ID: 25748080
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.